Company · CIK 0001636282 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Spyre Therapeutics, Inc. · SYRE
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 SForm 4 → | Sep 3, 9:34 pm EDT | Heidy King-JonesSee Remarks | 28,399 | $87.35 | $2,480,529 | 2,845 | −90.9% | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 3, 9:34 pm EDT | Heidy King-JonesSee Remarks | 28,399 | $14.50 | $411,786 | 3,245 | — | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 3, 9:33 pm EDT | Scott L BurrowsChief Financial Officer | 25,732 | $88.75 | $2,283,821 | 79,762 | −24.4% | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 3, 9:33 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $14.50 | $108,750 | 105,494 | — | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 3, 9:33 pm EDT | Cameron TurtleChief Executive Officer, Director | 15,000 | $87.29 | $1,309,410 | 552,540 | −2.64% | 10b5-1 |
| Aug 7, 2026 SForm 4 → | Aug 10, 9:31 pm EDT | Jeffrey W. AlbersDirector | 23,000 | $104.53 | $2,404,190 | 9,360 | −71.1% | 10b5-1 |
| Aug 7, 2026 MForm 4 → | Aug 10, 9:31 pm EDT | Jeffrey W. AlbersDirector | 5,000 | $10.39 | $51,950 | 5,000 | — | 10b5-1 |
| Aug 3, 2026 SForm 4 → | Aug 5, 9:32 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $95.57 | $716,771 | 97,994 | −7.11% | 10b5-1 |
| Aug 3, 2026 MForm 4 → | Aug 5, 9:32 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $14.50 | $108,750 | 105,494 | — | 10b5-1 |
| Aug 3, 2026 SForm 4 → | Aug 5, 9:31 pm EDT | Cameron TurtleChief Executive Officer, Director | 15,000 | $95.51 | $1,432,705 | 567,540 | −2.57% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 2, 9:33 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $87.74 | $658,040 | 97,994 | −7.11% | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 9:33 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $14.50 | $108,750 | 105,494 | — | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 2, 9:33 pm EDT | Sheldon SloanChief Medical Officer | 8,334 | $87.70 | $730,896 | 0 | −100% | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 9:33 pm EDT | Sheldon SloanChief Medical Officer | 8,334 | $27.46 | $228,852 | 8,334 | — | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 2, 9:32 pm EDT | Cameron TurtleChief Executive Officer, Director | 15,000 | $87.69 | $1,315,346 | 582,540 | −2.51% | 10b5-1 |
| Jun 25, 2026 SForm 4 → | Jun 26, 9:31 pm EDT | Scott L BurrowsChief Financial Officer | 15,000 | $87.13 | $1,307,000 | 97,994 | −13.3% | |
| Jun 25, 2026 MForm 4 → | Jun 26, 9:31 pm EDT | Scott L BurrowsChief Financial Officer | 15,000 | $14.50 | $217,500 | 112,994 | — | |
| Jun 23, 2026 SForm 4 → | Jun 23, 9:56 pm EDT | Fairmount Funds Management LLC +3Director | 4,684,781 | $85.31 | $399,658,667 | 0 | −100% | |
| Jun 23, 2026 CForm 4 → | Jun 23, 9:56 pm EDT | Fairmount Funds Management LLC +3Director | 666,680 | — | — | 4,684,781 | — | |
| Jun 22, 2026 SForm 4 → | Jun 23, 9:32 pm EDT | Michael Thomas HendersonDirector | 20,000 | $100.00 | $2,000,000 | 68,606 | −22.6% | 10b5-1 |
| Jun 3, 2026 SForm 4 → | Jun 3, 9:32 pm EDT | Sheldon SloanChief Medical Officer | 8,333 | $75.00 | $624,975 | 0 | −100% | 10b5-1 |
| Jun 3, 2026 MForm 4 → | Jun 3, 9:32 pm EDT | Sheldon SloanChief Medical Officer | 8,333 | $27.46 | $228,824 | 8,333 | — | 10b5-1 |
| Jun 1, 2026 SForm 4 → | Jun 3, 9:31 pm EDT | Cameron TurtleChief Executive Officer, Director | 15,000 | $70.43 | $1,056,486 | 597,540 | −2.45% | 10b5-1 |
| Jun 1, 2026 SForm 4 → | Jun 3, 9:30 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $71.06 | $532,937 | 97,994 | −7.11% | 10b5-1 |
| Jun 1, 2026 MForm 4 → | Jun 3, 9:30 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | $14.50 | $108,750 | 105,494 | — | 10b5-1 |
| Feb 6, 2019 MForm 4 → | Feb 8, 4:15 pm EST | Anthony G. QuinnPresident & CEO, Director | 8,756 | $6.18 | $54,126 | 276,433 | — | plan? |
| Dec 7, 2018 MForm 4 → | Dec 10, 5:40 pm EST | Anthony G. QuinnPresident & CEO, Director | 171,890 | $4.37 | $751,816 | 267,677 | — | plan? |
| Sep 27, 2018 SForm 4 → | Sep 28, 5:11 pm EDT | Aaron SchuchartChief Business Officer | 6,000 | $9.50 | $57,005 | 2,500 | −70.6% | plan? |
| Aug 17, 2018 MForm 4 → | Aug 21, 4:24 pm EDT | Aaron SchuchartChief Business Officer | 8,500 | $3.50 | $29,750 | 8,500 | — | plan? |
| Aug 13, 2018 MForm 4 → | Aug 15, 4:40 pm EDT | George GeorgiouDirector | 37,333 | $5.91 | $220,784 | 175,861 | — | plan? |
| Jul 12, 2018 MForm 4 → | Jul 16, 9:04 am EDT | Anthony G. QuinnInterim CEO, Director | 38,866 | $6.76 | $262,764 | 92,793 | — | plan? |
| Jul 11, 2018 MForm 4 → | Jul 13, 9:05 am EDT | Anthony G. QuinnInterim CEO, Director | 3,307 | $5.46 | $18,056 | 53,927 | — | plan? |
| May 11, 2018 SForm 4 → | May 14, 4:01 pm EDT | Novartis Bioventures Ltd +110% Owner | 19,550 | $10.06 | $196,673 | 2,175,314 | −0.89% | plan? |
| May 9, 2018 SForm 4 → | May 11, 4:28 pm EDT | Novartis Bioventures Ltd +110% Owner | 73,955 | $10.12 | $748,140 | 2,194,864 | −3.26% | plan? |
| May 7, 2018 SForm 4 → | May 9, 4:01 pm EDT | Novartis Bioventures Ltd +110% Owner | 42,105 | $10.06 | $423,557 | 2,268,819 | −1.82% | plan? |
| Feb 15, 2018 PForm 4 → | Dec 10, 5:40 pm EST | Anthony G. QuinnPresident & CEO, Director | 2,994 | $7.05 | $21,115 | 95,787 | +3.23% | plan? late |
| Feb 15, 2018 MForm 4 → | Feb 20, 4:36 pm EST | Anthony G. QuinnInterim CEO, Director | 15,211 | $5.46 | $83,052 | 50,620 | — | plan? |
| Dec 6, 2017 PForm 4 → | Dec 8, 7:06 pm EST | Anthony G. QuinnInterim CEO, Director | 8,288 | $4.96 | $41,078 | 35,409 | +30.6% | plan? |
| Dec 1, 2017 PForm 4 → | Dec 5, 9:04 pm EST | Anthony G. QuinnDirector | 17,121 | $4.86 | $83,177 | 27,121 | +171% | plan? |
| Feb 16, 2017 PForm 4 → | Feb 21, 5:58 pm EST | ORBIMED ADVISORS LLC +210% Owner | 109,300 | $5.16 | $563,882 | 1,469,524 | +8.04% | plan? |
| Aug 15, 2016 PForm 4 → | Dec 5, 2017, 9:07 pm EST | Charles N York IIChief Financial Officer and VP | 25,959 | $4.48 | $116,223 | 34,787 | +294% | plan? late |
| Apr 12, 2016 CForm 4/A → | Apr 14, 7:35 pm EDT | LILLY ELI & CO +210% Owner | 2,010,924 | — | — | 2,068,543 | — | plan? |
| Apr 12, 2016 PForm 4 → | Apr 14, 6:41 pm EDT | LILLY ELI & CO10% Owner | 500,000 | $10.00 | $5,000,000 | 2,568,543 | +24.2% | plan? |
| Apr 12, 2016 CForm 4 → | Apr 14, 6:41 pm EDT | LILLY ELI & CO10% Owner | 2,010,924 | — | — | 2,068,543 | — | plan? |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:15 pm EDT | Charles N York IIChief Financial Officer and VP | 12,884 | — | — | 11,560 | — | plan? |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:13 pm EDT | Joseph E TylerVP, Manufacturing | 31,260 | — | — | 42,428 | — | plan? |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:12 pm EDT | Scott W RowlinsonVP, Research | 11,204 | — | — | 11,204 | — | plan? |
| Apr 12, 2016 PForm 4 → | Apr 12, 5:10 pm EDT | Anthony QuinnDirector | 10,000 | $10.00 | $100,000 | 10,000 | — | plan? |
| Apr 12, 2016 PForm 4 → | Apr 12, 5:09 pm EDT | Novartis Bioventures Ltd +110% Owner | 300,000 | $10.00 | $3,000,000 | 2,310,924 | +14.9% | plan? |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:09 pm EDT | Novartis Bioventures Ltd +110% Owner | 2,010,924 | — | — | 2,010,924 | — | plan? |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:07 pm EDT | David George LoweCEO and President, Director | 5,658 | — | — | 5,658 | — | plan? |
| Apr 12, 2016 PForm 4 → | Apr 12, 5:06 pm EDT | Russell J. CoxDirector | 7,000 | $10.00 | $70,000 | 7,000 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 MForm 4 → | Sep 3, 9:34 pm EDT | Heidy King-JonesSee Remarks | 28,399 | — | — | 511,411 | — | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 3, 9:33 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | — | — | 337,357 | — | 10b5-1 |
| Aug 7, 2026 MForm 4 → | Aug 10, 9:31 pm EDT | Jeffrey W. AlbersDirector | 5,000 | — | — | 45,000 | — | 10b5-1 |
| Aug 3, 2026 MForm 4 → | Aug 5, 9:32 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | — | — | 344,857 | — | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 9:33 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | — | — | 352,357 | — | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 9:33 pm EDT | Sheldon SloanChief Medical Officer | 8,334 | — | — | 305,000 | — | 10b5-1 |
| Jun 25, 2026 MForm 4 → | Jun 26, 9:31 pm EDT | Scott L BurrowsChief Financial Officer | 15,000 | — | — | 359,857 | — | |
| Jun 23, 2026 CForm 4 → | Jun 23, 9:56 pm EDT | Fairmount Funds Management LLC +3Director | 16,667 | — | — | 0 | — | |
| Jun 3, 2026 MForm 4 → | Jun 3, 9:32 pm EDT | Sheldon SloanChief Medical Officer | 8,333 | — | — | 313,334 | — | 10b5-1 |
| Jun 1, 2026 MForm 4 → | Jun 3, 9:30 pm EDT | Scott L BurrowsChief Financial Officer | 7,500 | — | — | 374,857 | — | 10b5-1 |
| Mar 6, 2019 AForm 4 → | Mar 8, 4:41 pm EST | Leslie SloanChief Operating Officer | 36,000 | — | — | 36,000 | — | |
| Feb 28, 2019 AForm 4 → | Mar 1, 5:10 pm EST | Charles N York IIChief Financial Officer and VP | 87,600 | — | — | 87,600 | — | |
| Feb 28, 2019 AForm 4 → | Mar 1, 5:09 pm EST | James WooldridgeChief Medical Officer | 50,200 | — | — | 50,200 | — | |
| Feb 28, 2019 AForm 4 → | Mar 1, 5:09 pm EST | Aaron SchuchartChief Business Officer | 60,000 | — | — | 60,000 | — | |
| Feb 28, 2019 AForm 4 → | Mar 1, 5:08 pm EST | Anthony G. QuinnPresident & CEO, Director | 280,000 | — | — | 280,000 | — | |
| Feb 6, 2019 MForm 4 → | Feb 8, 4:15 pm EST | Anthony G. QuinnPresident & CEO, Director | 8,756 | — | — | 137,517 | — | |
| Dec 7, 2018 MForm 4 → | Dec 10, 5:40 pm EST | Anthony G. QuinnPresident & CEO, Director | 171,890 | — | — | 144,950 | — | |
| Aug 17, 2018 MForm 4 → | Aug 21, 4:24 pm EDT | Aaron SchuchartChief Business Officer | 8,500 | — | — | 91,500 | — | |
| Aug 13, 2018 MForm 4 → | Aug 15, 4:40 pm EDT | George GeorgiouDirector | 37,333 | — | — | 10,000 | — | |
| Jul 18, 2018 AForm 4 → | Jul 20, 5:26 pm EDT | Anthony G. QuinnPresident & CEO, Director | 500,000 | — | — | 50,000 | — | |
| Jul 13, 2018 AForm 4 → | Jul 17, 4:27 pm EDT | V Bryan LawlisDirector | 36,800 | — | — | 36,800 | — | |
| Jul 12, 2018 MForm 4 → | Jul 16, 9:04 am EDT | Anthony G. QuinnInterim CEO, Director | 38,866 | — | — | 163,534 | — | |
| Jul 11, 2018 MForm 4 → | Jul 13, 9:05 am EDT | Anthony G. QuinnInterim CEO, Director | 3,307 | — | — | 5,291 | — | |
| Jun 7, 2018 AForm 4 → | Jun 8, 6:47 pm EDT | Armen ShanafeltDirector, 10% Owner | 18,400 | — | — | 18,400 | — | |
| Jun 7, 2018 AForm 4 → | Jun 8, 6:45 pm EDT | Sandesh MahatmeDirector | 18,400 | — | — | 18,400 | — | |
| Jun 7, 2018 AForm 4 → | Jun 8, 6:44 pm EDT | George GeorgiouDirector | 18,400 | — | — | 18,400 | — | |
| Jun 7, 2018 AForm 4 → | Jun 8, 6:43 pm EDT | Russell J. CoxDirector | 18,400 | — | — | 18,400 | — | |
| Jun 7, 2018 AForm 4 → | Jun 8, 6:42 pm EDT | Suzanne Louise BruhnDirector | 18,400 | — | — | 18,400 | — | |
| Mar 22, 2018 AForm 4 → | Mar 26, 8:05 am EDT | Ivana MagovcevicDirector | 36,800 | — | — | 36,800 | — | |
| Feb 20, 2018 AForm 4 → | Feb 22, 6:25 pm EST | James WooldridgeChief Medical Officer | 45,000 | — | — | 45,000 | — | |
| Feb 20, 2018 AForm 4 → | Feb 22, 6:24 pm EST | Charles N York IIChief Financial Officer and VP | 92,100 | — | — | 92,100 | — | |
| Feb 20, 2018 AForm 4 → | Feb 22, 6:23 pm EST | Anthony G. QuinnInterim CEO, Director | 178,400 | — | — | 178,400 | — | |
| Feb 20, 2018 AForm 4 → | Feb 22, 6:22 pm EST | Aaron SchuchartChief Business Officer | 20,000 | — | — | 20,000 | — | |
| Feb 15, 2018 MForm 4 → | Feb 20, 4:36 pm EST | Anthony G. QuinnInterim CEO, Director | 15,211 | — | — | 8,598 | — | |
| Dec 1, 2017 AForm 4 → | Dec 5, 9:06 pm EST | Armen ShanafeltDirector, 10% Owner | 30,000 | — | — | 30,000 | — | |
| Dec 1, 2017 AForm 4 → | Dec 5, 9:03 pm EST | Sandesh MahatmeDirector | 30,000 | — | — | 30,000 | — | |
| Dec 1, 2017 AForm 4 → | Dec 5, 9:01 pm EST | George GeorgiouDirector | 30,000 | — | — | 30,000 | — | |
| Dec 1, 2017 AForm 4 → | Dec 5, 9:00 pm EST | Russell J. CoxDirector | 30,000 | — | — | 30,000 | — | |
| Aug 31, 2017 AForm 4 → | Sep 1, 5:10 pm EDT | Anthony G. QuinnInterim CEO, Director | 150,000 | — | — | 150,000 | — | |
| Aug 22, 2017 AForm 4 → | Aug 24, 6:04 pm EDT | Charles N York IIChief Financial Officer and VP | 58,500 | — | — | 58,500 | — | |
| Aug 22, 2017 AForm 4 → | Aug 24, 6:04 pm EDT | James WooldridgeChief Medical Officer | 175,000 | — | — | 10,000 | — | |
| Aug 22, 2017 AForm 4 → | Aug 24, 6:03 pm EDT | Joseph E TylerVP, Manufacturing | 25,000 | — | — | 25,000 | — | |
| Aug 22, 2017 AForm 4 → | Aug 24, 6:02 pm EDT | Aaron SchuchartChief Business Officer | 10,000 | — | — | 10,000 | — | |
| Aug 22, 2017 AForm 4 → | Aug 24, 6:02 pm EDT | Scott W RowlinsonVP, Research | 25,000 | — | — | 25,000 | — | |
| Jun 16, 2017 AForm 4 → | Jun 20, 5:06 pm EDT | Aaron SchuchartChief Business Officer | 100,000 | — | — | 100,000 | — | |
| Apr 21, 2017 AForm 4 → | Apr 25, 5:10 pm EDT | Anthony Quinninterim Chief Medical Officer, Director | 24,000 | — | — | 24,000 | — | |
| Mar 20, 2017 AForm 4 → | Mar 22, 5:00 pm EDT | Charles N York IIChief Financial Officer and VP | 90,000 | — | — | 90,000 | — | |
| Mar 20, 2017 AForm 4 → | Mar 22, 5:00 pm EDT | Joseph E TylerVP, Manufacturing | 39,000 | — | — | 39,000 | — | |
| Mar 20, 2017 AForm 4 → | Mar 22, 4:54 pm EDT | Scott W RowlinsonVP, Research | 60,000 | — | — | 60,000 | — | |
| Mar 20, 2017 AForm 4 → | Mar 22, 4:53 pm EDT | David George LoweCEO and President, Director | 160,000 | — | — | 160,000 | — | |
| Mar 20, 2017 AForm 4 → | Mar 22, 4:52 pm EDT | Henry HebelVP, Product Development | 38,200 | — | — | 38,200 | — | |
| Feb 15, 2017 AForm 4 → | Feb 16, 5:13 pm EST | Suzanne Louise BruhnDirector | 82,000 | — | — | 82,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:39 pm EDT | Charles N York IIChief Financial Officer and VP | 55,000 | — | — | 55,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:39 pm EDT | Joseph E TylerVP, Manufacturing | 33,000 | — | — | 33,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:38 pm EDT | Armen ShanafeltDirector, 10% Owner | 24,000 | — | — | 24,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:37 pm EDT | Scott W RowlinsonVP, Research | 47,000 | — | — | 47,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:37 pm EDT | Sandra Rojas-CaroChief Medical Officer | 200,000 | — | — | 200,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:35 pm EDT | Sandesh MahatmeDirector | 10,000 | — | — | 10,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:35 pm EDT | David George LoweCEO and President, Director | 160,000 | — | — | 160,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:34 pm EDT | Henry HebelVP, Product Development | 43,000 | — | — | 43,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:33 pm EDT | George GeorgiouDirector | 24,000 | — | — | 24,000 | — | |
| May 17, 2016 AForm 4 → | May 19, 4:33 pm EDT | Russell J. CoxDirector | 10,000 | — | — | 10,000 | — | |
| Apr 12, 2016 CForm 4 → | Apr 14, 6:41 pm EDT | LILLY ELI & CO10% Owner | 2,010,924 | — | — | 0 | — | |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:15 pm EDT | Charles N York IIChief Financial Officer and VP | 12,884 | — | — | 0 | — | |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:13 pm EDT | Joseph E TylerVP, Manufacturing | 31,260 | — | — | 0 | — | |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:12 pm EDT | Scott W RowlinsonVP, Research | 11,204 | — | — | 0 | — | |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:09 pm EDT | Novartis Bioventures Ltd +110% Owner | 2,010,924 | — | — | 0 | — | |
| Apr 12, 2016 CForm 4 → | Apr 12, 5:07 pm EDT | David George LoweCEO and President, Director | 5,658 | — | — | 0 | — |